COMMUNIQUÉS West-GlobeNewswire

Standard BioTools to Announce First Quarter 2026 Financial Results on May 5, 2026
21/04/2026
BOSTON, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish its first quarter 2026 financial results on Tuesday, May 5, 2026, after U.S. market close. [...]
Eupraxia Pharmaceuticals Reports Positive Nine-Month Tissue Health and Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis
21/04/2026
This is the first release of 36-week symptom response & tissue health data for the highest dose (Cohort 9) from the dose escalation portion of Eupraxia’s RESOLVE trial. At 36 weeks, patients in Cohort 9 (n=3) [...]
BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP
21/04/2026
120 mg and newly announced 60 mg once-daily doses each achieved ≥85% median hsCRP reductions in participants with obesity and elevated baseline inflammation BGE-102 was well tolerated across all dose levels Phase 2 [...]
Rezolute to Present Results from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism at the Pediatric Endocrine Society (PES) Annual Meeting
21/04/2026
Oral presentation will include previously announced topline results as well as pre-specified and post-hoc data updates REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” [...]
XORTX Meets Nasdaq Continued Listing Requirements
21/04/2026
CALGARY, Alberta, April 21, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on [...]
Independent Nonclinical Research on Lasofoxifene Presented at American Association for Cancer Research Annual Meeting 2026 Consistent with LeonaBio’s Data
21/04/2026
Results showed lasofoxifene protected against hormone withdrawal-induced bone loss and maintained a robust anti-tumor response in primary and metastatic animal models of ER+ breast cancer BOTHELL, Wash., April 21, 2026 [...]
Kala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic Medicine
21/04/2026
Historic U.S. Executive Order Fast-Tracks Psychedelic Research Access; Landmark Policy Shift Strengthens the Outlook for KALA’s Client Red Light Holland and Positions Researgency.ai as the Dedicated AI Infrastructure [...]
Promatix Biosciences Highlights the Power of its Logic-Gated Proteomics-Driven Bispecific Discovery Platform to Expand the Tumour-Selective Target Space for Next-Generation ADCs at AACR 2026
21/04/2026
Promatix Biosciences Highlights the Power of its Logic-Gated Proteomics-Driven Bispecific Discovery Platform to Expand the Tumour-Selective Target Space for Next-Generation ADCs at AACR 2026 Scarcity of truly tumour- [...]
RAMSAY SANTE : mise à disposition du rapport financier semestriel au 31 décembre 2025
21/04/2026
Paris, le 21 avril 2026 RAMSAY SANTE Mise à disposition du rapport financier semestriel au 31 décembre 2025 Ce document est disponible sur le site internet de RAMSAY SANTE : http://www.ramsaysante.fr À propos de Ramsay [...]
RAMSAY SANTE : Half-year Financial Report as at end of December 2025 disposal
21/04/2026
Paris, April 21, 2026 RAMSAY SANTE Half-year Financial Report as at end of December 2025 disposal This document is available on RAMSAY SANTE Internet site : http://www.ramsaysante.fr About Ramsay Santé Ramsay Santé is [...]
Nobel-Potential Discovery from VectorBuilder Scientists Reveals Fundamental Mechanisms of Development
21/04/2026
CHICAGO, April 21, 2026 (GLOBE NEWSWIRE) -- One of the most fundamental questions in biology is how a single fertilized egg produces the diverse cell types making up the body – from neurons and skin to muscle and blood [...]
Preclinical Data of Novel B7-H3 ADC ICP-B794 Unveiled at 2026 AACR, Demonstrating Superior Anti-Tumor Activity and Safety
21/04/2026
BEIJING, April 21, 2026 (GLOBE NEWSWIRE) -- At the 2026 American Association for Cancer Research (AACR) Annual Meeting, InnoCare Pharma (HKEX: 9969; SSE: 688428) presented preclinical data of its novel B7-H3 targeted [...]
Dark Horse Consulting Group’s Acquisition of CJ PARTNERS Provides Regional Expansion
21/04/2026
WALNUT CREEK, Calif. and TOKYO, April 21, 2026 (GLOBE NEWSWIRE) -- Dark Horse Consulting Group (“DHCG” or “the Group”) today announced the acquisition of CJ PARTNERS (“CJP”), a distinguished consulting and advisory firm [...]
Hyalex Orthopaedics Announces FDA 510(k) Clearance of the HYALEX Slalom™ MTP Hemiarthroplasty System
21/04/2026
Regulatory milestone positions company for initial commercial entry into large and underserved foot & ankle market LEXINGTON, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Hyalex Orthopaedics today announced that it has [...]
Amphista Therapeutics presents the discovery, characterisation and chemical structure of AMX-883, an orally bioavailable, highly potent and selective DCAF16 degrader of BRD9 at AACR 2026
21/04/2026
First public disclosure of the chemical structure of AMX-883, an orally bioavailable, highly potent and selective DCAF16-dependent Targeted Glue™ degrader of BRD9 AMX-883 is the Company’s lead asset entering a Phase I [...]
Avricore Health Achieves Milestones and Outlines UK Expansion Roadmap for HealthTab™ Platform
21/04/2026
VANCOUVER, British Columbia, April 21, 2026 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the " Company " or “ Avricore ”) announces HealthTab™ has now screened more than 3,500 patients in community pharmacies [...]
AAVantgarde announces completion of recruitment in STELLA natural history study
21/04/2026
MILAN, April 21, 2026 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company pioneering next-generation gene therapies for inherited retinal diseases (IRDs) has today announced the [...]
Xeltis receives CE mark for aXess™, its aXess hemodialysis conduit™, as it moves to commercialization
21/04/2026
CE mark awarded for aXess™ at record speed, underpinned by strong EU pivotal trial data Xeltis advances ahead of schedule to commercialization aXess™ reduces the need for vascular access interventions enabling more [...]
Amphista Therapeutics presents the discovery, characterisation and chemical structure of AMX-883, an orally bioavailable, highly potent and selective DCAF16 degrader of BRD9 at AACR 2026
21/04/2026
First public disclosure of the chemical structure of AMX-883, an orally bioavailable, highly potent and selective DCAF16-dependent Targeted Glue™ degrader of BRD9 AMX-883 is the Company’s lead asset entering a Phase I [...]

Pages